Lapatinib and Epirubicin in Treating Patients With Metastatic Breast Cancer. ICORG 06-30
Status:
Completed
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Lapatinib may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth. Drugs used in chemotherapy, such as epirubicin, work in different
ways to stop the growth of tumor cells, either by killing the cells or by stopping them from
dividing. Giving lapatinib together with epirubicin may kill more tumor cells.
PURPOSE: This phase I trial is studying the side effects and best dose of epirubicin when
given together with lapatinib in treating patients with metastatic breast cancer.